Zura Bio (ZURA) Projected to Post Earnings on Wednesday

Zura Bio (NASDAQ:ZURA) will likely be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Performance

ZURA stock opened at $5.68 on Tuesday. Zura Bio has a one year low of $0.97 and a one year high of $7.44. The firm’s fifty day moving average is $6.25 and its 200 day moving average is $4.72. The firm has a market cap of $538.92 million, a PE ratio of -5.36 and a beta of 0.18.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Oppenheimer dropped their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Wedbush assumed coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price target on the stock. Chardan Capital raised their price objective on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Insider Buying and Selling at Zura Bio

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This represents a 43.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zura Bio

Hedge funds have recently made changes to their positions in the company. Insigneo Advisory Services LLC purchased a new stake in shares of Zura Bio during the fourth quarter worth approximately $292,000. Alps Advisors Inc. purchased a new position in Zura Bio in the 4th quarter valued at $280,000. Barclays PLC lifted its holdings in Zura Bio by 2,432,950.0% in the 4th quarter. Barclays PLC now owns 48,661 shares of the company’s stock valued at $255,000 after purchasing an additional 48,659 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in Zura Bio during the 4th quarter worth $246,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Zura Bio during the fourth quarter worth $192,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.